Date published: 2025-11-4

1-800-457-3801

SCBT Portrait Logo
Seach Input

JMJD3 Inhibitors

The chemical class of JMJD3 Inhibitors is characterized by compounds that can interfere with the enzymatic activity of JMJD3, thereby affecting the methylation status of histone proteins. These inhibitors operate through various mechanisms, including direct binding to the enzyme's active site, chelation of the catalytically essential metal ions, competition with co-factors or substrates, or by acting as analogs that mimic the natural substrates or products of the enzymatic reaction. The end effect of these inhibitors is the maintenance of methyl marks on H3K27, which is associated with the repression of gene expression. The direct inhibitors such as GSK-J1 and its prodrug GSK-J4 are designed to bind specifically to the active site of JMJD3, blocking its ability to demethylate H3K27me3. Broad-spectrum inhibitors like IOX1 and DMOG are less selective and inhibit a range of 2-oxoglutarate-dependent dioxygenases, including JMJD3, by competing with the co-factor 2-oxoglutarate. Hydroxamic acids function by chelating the iron ions that are crucial for the catalytic activity of JMJD3, thereby blocking the demethylation reaction. Disulfiram and bipyridyl also act by metal chelation, disrupting the metal-dependent enzymatic activity of JMJD3.The indirect inhibition mechanisms involve the modulation of cellular pathways that affect JMJD3 activity. For example, by interfering with the synthesis of S-adenosylmethionine (SAM), a universal methyl donor, compounds like methylthioadenosine can indirectly influence JMJD3 activity and the methylation state of histones. Similarly, compounds that compete with 2-oxoglutarate or bind to the iron in the JMJD3 active site can lead to an overall decrease in JMJD3 activity, thus affecting the dynamic equilibrium of methyl marks on histones and the expression of genes regulated by H3K27me3 methylation. The development and study of JMJD3 inhibitors are of interest due to their ability to modulate epigenetic marks and thereby alter gene expression profiles. The ability to maintain the methylation of H3K27me3 has implications for the study of developmental biology, oncogenesis, and other processes where gene regulation plays a critical role. The specificity and selectivity of these inhibitors are crucial for their utility in research, as off-target effects could lead to unintended consequences due to the pervasive role of methylation in cellular regulation.
Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

GSK J1

1373422-53-7sc-391113
sc-391113A
10 mg
50 mg
$189.00
$797.00
(0)

GSK J1 acts as a selective inhibitor of JMJD3, showcasing a unique mechanism of action through its ability to stabilize the enzyme's inactive conformation. This compound engages in specific hydrogen bonding and electrostatic interactions, which modulate the enzyme's catalytic activity. Its kinetic profile reveals a slow dissociation rate, promoting sustained inhibition. Additionally, GSK J1's lipophilic characteristics enhance its membrane permeability, facilitating cellular uptake and interaction with target pathways.

GSK J4

sc-391114
sc-391114A
10 mg
50 mg
$215.00
$860.00
5
(1)

GSK J4 serves as a potent inhibitor of JMJD3, characterized by its ability to disrupt the enzyme's active site through unique steric hindrance. This compound exhibits a distinctive binding affinity, leading to altered reaction kinetics that favor prolonged enzyme inhibition. Its hydrophobic interactions contribute to a favorable conformational change, enhancing selectivity. GSK J4's structural features allow for specific molecular recognition, influencing downstream signaling pathways effectively.

5-Carboxy-8-hydroxyquinoline

5852-78-8sc-397023
5 mg
$86.00
(0)

5-Carboxy-8-hydroxyquinoline acts as a selective inhibitor of JMJD3, showcasing unique chelation properties that facilitate strong interactions with metal ions in the enzyme's active site. This compound's ability to form stable complexes alters the enzyme's conformation, impacting its catalytic efficiency. Additionally, its polar functional groups enhance solubility, promoting effective diffusion in biological systems and influencing substrate accessibility.

JIB 04

199596-05-9sc-397040
20 mg
$177.00
(0)

JIB 04 is a cell permeable and selective Jumonji histone demethylase inhibitor

2,4-Pyridinedicarboxylic acid monohydrate

207671-42-9sc-225693
1 g
$28.00
(0)

It can act as a competitive inhibitor to the 2-oxoglutarate co-factor, potentially reducing JMJD3 activity.

Suberoylanilide Hydroxamic Acid

149647-78-9sc-220139
sc-220139A
100 mg
500 mg
$130.00
$270.00
37
(2)

Suberoylanilide Hydroxamic Acid can chelate the iron in the JMJD3 active site, potentially inhibiting its histone demethylase activity.

Disulfiram

97-77-8sc-205654
sc-205654A
50 g
100 g
$52.00
$87.00
7
(1)

Disulfiram can inhibit JMJD3 by chelating the active site metal ions required for its enzymatic activity.

5′-Deoxy-5′-methylthioadenosine

2457-80-9sc-202427
50 mg
$120.00
1
(1)

As a byproduct of polyamine synthesis, it can indirectly inhibit JMJD3 activity through feedback mechanisms on SAM-dependent methylases.

Dimethyloxaloylglycine (DMOG)

89464-63-1sc-200755
sc-200755A
sc-200755B
sc-200755C
10 mg
50 mg
100 mg
500 mg
$82.00
$295.00
$367.00
$764.00
25
(2)

DMOG is a cell-permeable inhibitor of 2-oxoglutarate-dependent dioxygenases, which could indirectly inhibit JMJD3 activity.